Fortress Biotech (FBIO) vs Spero Therapeutics (SPRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Fortress Biotech (FBIO) has outperformed Spero Therapeutics (SPRO) over the past year, losing 33.1% versus a loss of 45.8%. Over five years, SPRO leads with a -93.1% price change compared with -95.6% for FBIO. Fortress Biotech is the larger company by market cap ($69.4 million vs $67.0 million), about 1.0 times the size.
On valuation, Fortress Biotech trades at a lower trailing P/E (0.8x vs 8.2x for Spero Therapeutics).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FBIO | SPRO |
|---|---|---|
| Share price | $2.08 | $1.15 |
| Market cap | $69.37M | $66.98M |
| 1-day change | +1.96% | -1.70% |
| YTD return | -44.26% | -49.79% |
| 1-year return | -33.11% | -45.83% |
| 5-year return | -95.58% | -93.13% |
| P/E ratio (TTM) | 0.75 | 8.22 |
| EPS (TTM) | $2.76 | $0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.53 | $3.08 |
| 52-week low | $2.00 | $1.08 |
| Distance from 52-week high | -54.08% | -62.66% |
| Average volume | 507.86K | 1.20M |
| Shares outstanding | 33.35M | 58.23M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FBIO has outperformed SPRO by 12.7 percentage points over the past year.
- Spero Therapeutics trades at a higher earnings multiple (8.2x vs 0.8x trailing P/E).
FBIO vs SPRO FAQ
Which is bigger, Fortress Biotech or Spero Therapeutics?
Fortress Biotech (FBIO) is larger, with a market capitalization of $69.37M compared with $66.98M for Spero Therapeutics (SPRO).
Which stock has performed better over the past year, FBIO or SPRO?
FBIO returned -33.11% over the past 12 months, compared with -45.83% for SPRO (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, FBIO or SPRO?
FBIO has the lower trailing P/E at 0.8, versus 8.2 for SPRO. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Fortress Biotech and Spero Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.